CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is viewed positively because CTX310 has shown durable one-time gene-editing effects, including a mean 78.6% reduction in ANGPTL3 one year post-dose at the highest tested dose, with no new treatment-related adverse events or delayed liver toxicity through 12 months. The data also suggest broad lipid benefit across triglycerides, LDL-C, and ApoB, strengthening its case in severe hypertriglyceridemia and refractory hypercholesterolemia versus recurring siRNA or other chronic approaches. Beyond the lipid franchise, Casgevy’s launch is expected to accelerate and management sees it reaching more than $1B in global sales by 2030, while multiple clinical-stage programs could support longer-term upside.

CRISPR Therapeutics is viewed negatively because its investment case remains heavily dependent on unproven, early-stage pipeline assets while Casgevy sales are assumed not to accelerate enough to offset the risk. Although CTX310 showed durable ANGPTL3 and lipid reductions through 12 months and CTX310 data were promising at AHA25, the cohorts were very small, some lipid effects were inconsistent, and durability remains a key uncertainty across the broader platform. The company also faces meaningful downside from intellectual property uncertainty, clinical setback risk, reliance on partners like Vertex and Bayer, and likely dilution from additional equity financing to fund development.